MBManon Breau-Brunel

Manon Breau-Brunel

*This is an algorithmically generated author record based on publicly available information.

Manon Breau-Brunel has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France

    by Gérard de Pouvourville, Manon Breau-Brunel, Véronique Loncle-Provot, Ekkehard Beck, Loïg Gaugain, Gaëlle Nachbaur, Céline Pribil

    Background and Objectives In France, meningococcal serogroup B (MenB) is the most common serogroup causing invasive meningococcal disease (IMD) in infants and young children. Our objective was to illustrate the impact of model choices on health outcomes and the cost-effectiveness of infant vaccination with the multicomponent meningococcal serogroup B vaccine (4CMenB) versus no vaccine in France. Methods A previously published dynamic transmission-based cost-effectiveness model was adapted for the French context using updated, French-specific demographic, epidemiological, and cost data. IMD incidence and long-term sequelae were derived through analysis of French healthcare and surveillance databases. A collective perspective over a 100-year time horizon was adopted, with a discount rate of 2.5%, reduced to 1.5% after the first 30 years. Deterministic and probabilistic sensitivity and scenario analyses were performed. Results In the base case analysis, infant vaccination with 4CMenB avoided 3101 MenB IMD cases in infants aged < 1 year (− 54%) and 6845 cases in all age groups (− 21%). The estimated incremental cost-effectiveness ratio was €316,272/quality-adjusted life-year (QALY) but was highly sensitive to the types of sequelae included, MenB incidence, vaccine effectiveness parameters, and consideration of life-expectancy in IMD survivors (range: €65,272/QALY to €493,218/QALY). Conclusions Using economic models compliant with French methodology guidelines, 4CMenB does not seem cost-effective; however, results are sensitive to model choices and 4CMenB immunization is an effective strategy to prevent MenB IMD cases and to improve quality of life and economic burden associated with MenB IMD treatment, especially with regard to long-term sequelae.


  • Top Cited Papers
    Open Access

    Unlocking the Value: Quantifying the Return on Investment of Hospital Artificial Intelligence

    by Prateek Bharadwaj, Lauren Nicola, Manon Breau-Brunel, Federica Sensini, Neda Tanova-Yotova, Petar Atanasov, Franziska Lobig, Michael Blankenburg